BioAtla (NASDAQ:BCAB) Issues Earnings Results

BioAtla (NASDAQ:BCAB) released its quarterly earnings results on Tuesday. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.20, FiscalAI reports. The firm had revenue of $2.00 million for the quarter, compared to analyst estimates of $0.70 million.

BioAtla Stock Performance

BioAtla stock traded up $0.01 during trading on Tuesday, hitting $0.16. The company’s stock had a trading volume of 1,165,021 shares, compared to its average volume of 1,276,868. The stock’s fifty day moving average is $0.20 and its 200 day moving average is $0.53. BioAtla has a 1-year low of $0.13 and a 1-year high of $1.43. The stock has a market capitalization of $10.22 million, a price-to-earnings ratio of -0.14 and a beta of 1.08.

Analysts Set New Price Targets

BCAB has been the subject of a number of analyst reports. Rodman & Renshaw assumed coverage on shares of BioAtla in a research report on Tuesday, January 13th. They issued a “buy” rating and a $4.00 price objective for the company. Weiss Ratings restated a “sell (d-)” rating on shares of BioAtla in a research report on Friday, January 9th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, BioAtla currently has an average rating of “Hold” and a consensus target price of $4.00.

Institutional Trading of BioAtla

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its stake in shares of BioAtla by 9.1% during the 3rd quarter. Vanguard Group Inc. now owns 1,945,795 shares of the company’s stock valued at $1,339,000 after acquiring an additional 162,647 shares during the last quarter. Acadian Asset Management LLC boosted its position in shares of BioAtla by 968.9% in the first quarter. Acadian Asset Management LLC now owns 1,690,110 shares of the company’s stock worth $585,000 after acquiring an additional 1,531,994 shares during the last quarter. Marshall Wace LLP acquired a new stake in shares of BioAtla in the fourth quarter worth approximately $508,000. Millennium Management LLC grew its holdings in BioAtla by 123.4% in the fourth quarter. Millennium Management LLC now owns 762,394 shares of the company’s stock valued at $433,000 after purchasing an additional 421,072 shares during the period. Finally, Jane Street Group LLC grew its holdings in BioAtla by 55.4% in the fourth quarter. Jane Street Group LLC now owns 346,774 shares of the company’s stock valued at $197,000 after purchasing an additional 123,597 shares during the period. Hedge funds and other institutional investors own 77.23% of the company’s stock.

BioAtla Company Profile

BioAtla, Inc (NASDAQ: BCAB) is a clinical‐stage biotechnology company focused on the development of conditionally active biologics (CABs) for oncology and other serious diseases. Utilizing its proprietary CAB technology platform, BioAtla engineers monoclonal antibodies, bispecifics and antibody-drug conjugates that remain inactive in healthy tissues but become activated in the tumor microenvironment. This targeted approach aims to improve therapeutic index by enhancing anti‐tumor potency while minimizing off-target effects and systemic toxicity.

Founded in 2012 and headquartered in San Diego, California, BioAtla has advanced multiple product candidates into clinical trials.